Pasal Wealth
Qualitek Labs Limited
A testing, inspection, and certification (TIC) company founded in 2018 — serving automotive, defence, pharma, and food sectors — listed on BSE SME in January 2024 at ₹100, trading near ₹369, with the first JSS 55555 accreditation for defence equipment testing in India.
Company Description
Qualitek Labs provides testing, inspection, homologation, certification, and consultancy services across a wide range of regulated industries: automotive, defence, metals and metallurgy, environment and water, minerals, food and agriculture, and pharma and healthcare.
The company was incorporated on May 17, 2018 as a private limited company in New Delhi, converted to a public limited company in April 2023, and listed on the BSE SME platform in January 2024 at an IPO price of ₹100 per share (listing gain: 90% on day one, listing price ₹190).
Its most notable credential: it was the first company in India to receive JSS 55555 accreditation for testing defence equipment for the Government of India — a standard-setting achievement in a tightly regulated, nationally strategic sector. The company currently operates two testing laboratories in Pune and Bhubaneshwar, with plans for further expansion in Pune and Noida.
Note: A conflict-of-interest disclosure in the company's RHP states that its promoters and directors also hold interest in a group company — Interstellar Testing Centre Private Limited — which is engaged in a similar business. This is a material disclosure worth reading directly in the company's original filings.
We reached out to Qualitek Labs management with four plain questions. When they respond, answers will appear here in full, unedited, clearly labelled as management's own words.
Company Numbers
Source: Public exchange filings and company financial data, as reported. Verify against latest filings before relying on any figure here.
Worth watching: Promoter holding of 56.5% is relatively low for a company of this size and age. A disclosed conflict of interest (group company in same business) requires reading the original RHP and latest filings. Revenue of ₹125 Cr against a ₹524 Cr market cap implies significant growth expectations are already priced in.
Company Performance
Source: Screener.in and public company disclosures. Pre-listing figures (FY22, FY23) are from the company's RHP and available public data. FY24 and FY25 are from post-listing exchange filings. Revenue grew 61% and PAT grew 161% between FY22 and FY23 per company disclosures. These are reported figures, not Pasal Wealth's projections.
Why almost nobody's looked at this yet
- 01India's TIC sector is genuinely under-covered by retail investors. Testing, inspection, and certification is a ₹15,000+ Cr industry in India growing with manufacturing and defence — but almost no retail investor tracks it as an investment category.
- 02First JSS 55555 accreditation for defence testing in India. This is a genuinely differentiated credential in a sector where government accreditation creates durable competitive barriers. It has received almost no financial media coverage.
- 03BSE SME listing keeps it outside mainstream research. Listed January 2024 on the SME platform. Most institutional research and retail screeners don't track SME-listed companies until they migrate to the mainboard.